NICE has launched a new consultation on the use of CYP2C19 genotype testing to guide treatment after a stroke or transient ischaemic attack (TIA) or ‘mini-stroke’.
CYP2C19 testing is carried out to see if patients will have resistance to treatment with clopidogrel, an anti-platelet therapy that is recommended by NICE as a treatment option for people at risk of a secondary stroke.
